ReviewThe Journal of allergy and clinical immunology2016
Vaccine development for allergen-specific immunotherapy based on recombinant allergens and synthetic allergen peptides: Lessons from the past and novel mechanisms of action for the future.
Review in The Journal of allergy and clinical immunology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 77 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
77 citing papers in PubMed, 179 citations in OpenAlex.
- Maternal allergen-specific IgG might protect the child against allergic sensitization.The Journal of allergy and clinical immunology · 2019Trial
- Safety and efficacy of immunotherapy with the recombinant B-cell epitope-based grass pollen vaccine BM32.The Journal of allergy and clinical immunology · 2018Trial
- Treating cat allergy with monoclonal IgG antibodies that bind allergen and prevent IgE engagement.Nature communications · 2018Trial
- Single-allergen sublingual immunotherapy versus multi-allergen subcutaneous immunotherapy for children with allergic rhinitis.Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban · 2017Trial
- Development of morphologically restored and deproteinized Juglans regia pollen-derived sporopollenin exine capsules: A multi-analytical verification study.Scientific reports · 2026Article
- Development of a Ferritin-Based Nano-Allergen and Its Immunological Effects in vitro and in vivo.International journal of nanomedicine · 2025Article
- Designing multifunctional recombinant vaccines: an engineering strategy based on innovative epitope prediction-guided splicing.Theranostics · 2025Article
- Novel Approaches to Allergen Immunotherapy for Respiratory Allergies.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Article
- Oral Administration ofAllergy, asthma & immunology research · 2024Article
- Characterization of Hum j 6, a Major Allergen FromAllergy, asthma & immunology research · 2023Article
- Allergen-specific immunotherapy by recombinant Der P1 allergen-derived peptide-based vaccine in an allergic mouse model.Immunity, inflammation and disease · 2023Article
- New approaches to immunotherapy in house dust mite allergy.Clinical and experimental pediatrics · 2023Article
- IgE and IgG4 Epitopes of Dermatophagoides and Blomia Allergens before and after Sublingual Immunotherapy.International journal of molecular sciences · 2023Article
- Potential and limitations of epitope mapping and molecular targeting in Hymenoptera venom allergy.Frontiers in allergy · 2023Review
- Adoptive transfer of allergen-expressing B cells prevents IgE-mediated allergy.Frontiers in immunology · 2023Article
- IgG in the control of FcεRI activation: a battle on multiple fronts.Frontiers in immunology · 2023Review
- How the Immune System Responds to Allergy Immunotherapy.Biomedicines · 2022Review
- Immune epitopes identification and designing of a multi-epitope vaccine against bovine leukemia virus: a molecular dynamics and immune simulation approaches.Cancer immunology, immunotherapy : CII · 2022Article
- Studies on HBcAg-rBlo t 5-21 Fusion Protein Vaccine That AlleviatesJournal of inflammation research · 2022Article
17 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
In the past, the development of more effective, safe, convenient, broadly applicable, and easy to manufacture vaccines for allergen-specific immunotherapy (AIT) has been limited by the poor quality of natural allergen extracts. Progress made in the field of molecular allergen characterization has now made it possible to produce defined vaccines for AIT and eventually for preventive allergy vaccination based on recombinant DNA technology and synthetic peptide chemistry. Here we review the characteristics of recombinant and synthetic allergy vaccines that have reached clinical evaluation and discuss how molecular vaccine approaches can make AIT more safe and effective and thus more convenient. Furthermore, we discuss how new technologies can facilitate the reproducible manufacturing of vaccines of pharmaceutical grade for inhalant, food, and venom allergens. Allergy vaccines in clinical trials based on recombinant allergens, recombinant allergen derivatives, and synthetic peptides allow us to target selectively different immune mechanisms, and certain of those show features that might make them applicable not only for therapeutic but also for prophylactic vaccination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.